News Antengene Corporation Limited

Equities

6996

KYG039571008

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-16 am EDT			5-day change	1st Jan Change
0.91 ^HKD	-2.15%		-3.19%	-54.50%

Mar. 22	Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress across First-in-Class, Best-in-Class Pipeline	Mar. 25	AQ
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	Mar. 20	CI
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms	Mar. 07	AQ
Antengene Announces Inclusion of XPOVIO in 2023 China's National Reimbursement Drug List	Dec. 15	AQ
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List	Dec. 13	MT
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List	Dec. 13	PR
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance	Dec. 13	CI
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	Dec. 11	AQ
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	Dec. 10	CI
Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and or Refractory Multiple Myeloma	Dec. 07	AQ
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma	Dec. 06	PR
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	Dec. 06	CI
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	Nov. 20	AQ
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	Nov. 16	PR
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	Nov. 16	CI
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs	Nov. 07	PR
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting	Oct. 31	PR
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting	23-09-27	PR
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031	23-09-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Antengene Corporation Limited

Equities

6996

KYG039571008

Summary

Filters